Aktieanalys

Scandinavian ChemoTech: Weathering the storm - Redeye

Redeye Publicerad: 22 Mar 07:38

Redeye provides a research update on Scandinavian ChemoTech following the Q4 2023 report and the retracted sales target in India. The company delivered a quarterly report that fell short of Redeye's estimates. Sales came in lower than anticipated, and OPEX was slightly higher, most likely due to some one-off items. On the positive note, a fifth commercial installation has been carried out on the US market and a TAM-expanding amendment to the study protocol at AIIMS Jodhpur has been announced.

Länk till analysen i sin helhet: https://www.redeye.se/research/970138/scandinavian-chemotech-weathering-the-storm?utm_source=finwire&utm_medium=RSS

Nyheter om ChemoTech

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!